An Infant Presents With Abdominal Distention & Enlarged Kidneys

Poll

A full-term infant presents with abdominal distention and enlarged kidneys. After further evaluation, a biopsy is performed. What is your diagnosis?

A full-term infant presents with abdominal distention and enlarged kidneys. According to the histopathology image below, what is your diagnosis?

What is your diagnosis?

A. Wilms tumor
B. Renal cell carcinoma
C. Neuroblastoma
D. Multicystic kidneys

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Related Content
Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.

Benmelstobart Combo Elicits PFS Advantage in Untreated Advanced ccRCC

Roman Fabbricatore
September 6th 2025
Article
Beyond the BEP: A Deep Dive into Testicular Cancer Management

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Nabil Adra, MD
September 6th 2025
Podcast
Additional correlative data and further prospective clinical investigations are needed to inform biomarker-directed advanced RCC treatment.

Pembrolizumab Combo Exhibits Sustained Clinical Benefit in Advanced RCC

Roman Fabbricatore
September 6th 2025
Article
Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
September 6th 2025
Podcast
Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Roman Fabbricatore
September 6th 2025
Article
The biomarker analysis in KEYNOTE-426 showed that pembrolizumab plus axitinib therapy is associated with positive outcomes with angiogenesis in RCC.

Pembrolizumab/Axitinib Improves Survival vs Sunitinib in Advanced RCC

Tim Cortese
September 6th 2025
Article